Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Mol Carcinog ; 51(7): 576-85, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21769948

RESUMEN

Retinoblastoma (Rb) is a common childhood intraocular cancer that affects approximately 300 children each year in the United States alone. 2-Methoxyestradiol (2ME), an endogenous metabolite of 17-ß-estradiol that dose not bind to nuclear estrogen receptor, exhibits potent apoptotic activity against rapidly growing tumor cells. Here, we report that 2ME induction of apoptosis was demonstrated by early fragmented DNA after 48 h of incubation with 10 µM 2ME in Rb cell lines. Subsequently, a decrease of proliferation was observed in a time- and dose-dependent manner. Further analysis of the mechanism indicates that p38 kinase plays a critical role in 2ME-induced apoptosis in Y79 cells, even though ERK was also activated by 2ME under the same conditions. Activation of p38 kinase also mediates 2ME induced Bax phosphorylated at Thr(167) after a 6 h treatment of 2ME, which in turn prevents formation of the Bcl-2-Bax heterodimer. Both p38 specific inhibitor, SB 203580, or p38 knockdown by specific siRNA, blocked 2ME induction of Bax phosphorylation. Furthermore, only transiently transfected mutant BaxT167A, but not Bax S163A, inhibited 2ME-induced apoptosis. In summary, our data suggest that 2ME induces apoptosis in human Rb cells by causing phosphorylation of p38 Mitogen-activated protein kinase (MAPK), which appears to be correlated with phosphorlation of Bax. This understanding of 2ME's ability may help develop it as a promising therapeutic candidate by inducing apoptosis in a Rb.


Asunto(s)
Apoptosis/efectos de los fármacos , Estradiol/análogos & derivados , Retinoblastoma/metabolismo , Proteína X Asociada a bcl-2/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo , 2-Metoxiestradiol , Secuencia de Bases , Western Blotting , Línea Celular Tumoral , Cartilla de ADN , Activación Enzimática , Estradiol/farmacología , Humanos , Mutagénesis Sitio-Dirigida , Fosforilación , ARN Interferente Pequeño , Retinoblastoma/enzimología , Retinoblastoma/patología
2.
PLoS One ; 8(2): e57073, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23468913

RESUMEN

Cartilage Link Protein 1 (Crtl1) is an extracellular matrix (ECM) protein that stabilizes the interaction between hyaluronan and versican and is expressed in endocardial and endocardially-derived cells in the developing heart, including cells in the atrioventricular (AV) and outflow tract (OFT) cushions. Previous investigations into the transcriptional regulation of the Crtl1 gene have shown that Sox9 regulates Crtl1 expression in both cartilage and the AV valves. The cardiac transcription factor Mef2c is involved in the regulation of gene expression in cardiac and skeletal muscle cell lineages. In this study we have investigated the potential role of Mef2c in the regulation of ECM production in the endocardial and mesenchymal cell lineages of the developing heart. We demonstrate that the Crtl1 5' flanking region contains two highly conserved Mef2 binding sites and that Mef2c is able to bind to these sites in vivo during cardiovascular development. Additionally, we show that Crtl1 transcription is dependent on Mef2c expression in fetal mitral valve interstitial cells (VICs). Combined, these findings highlight a new role for Mef2c in cardiac development and the regulation of cardiac extracellular matrix protein expression.


Asunto(s)
Proteínas de la Matriz Extracelular/genética , Regulación del Desarrollo de la Expresión Génica , Corazón/embriología , Miocardio/metabolismo , Factores Reguladores Miogénicos/metabolismo , Proteoglicanos/genética , Transcripción Genética , Animales , Secuencia de Bases , Sitios de Unión , Línea Celular , Endocardio/metabolismo , Factores de Transcripción MEF2 , Ratones , Datos de Secuencia Molecular , Células 3T3 NIH , Regiones Promotoras Genéticas , Unión Proteica , Alineación de Secuencia , Activación Transcripcional
3.
Acta Diabetol ; 49(3): 205-14, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21538163

RESUMEN

Endothelial cell (EC) survival is critical in the maintenance of endothelial function as well as in the regulation of angiogenesis and vessel integrity since endothelial dysfunction is the initial lesion of atherosclerosis. The goal of this study was to examine the effect of diazoxide, a mitochondrial ATP-sensitive K(+)(mito K(ATP)) channel opener, on aorta ECs apoptosis and its potential mechanism in Otsuka Long-Evans Tokushima Fatty (OLETF) rats at prediabetic stage. Diazoxide (25 mg kg(-1) day(-1)) was administered intraperitoneally from age 8 weeks to age 30 weeks. Thoracic aorta and cultured thoracic aortic ECs were used. The thickening of thoracic aortic wall and apoptosis of ECs were markedly increased in OLETF rats early from the age of 16 weeks, at the impaired glucose tolerance stage, compared with Long-Evans Tokushima Otsuka rats, in conjunction with intimal hyperplasia and perivascular fibrosis. In contrast, diazoxide treatment inhibited these changes. Further study strongly demonstrated that extracellular signal-regulated kinases (ERKs) are key regulatory proteins in protecting ECs from apoptosis. Diazoxide could significantly enhance phosphorylation of ERK via opening mito K(ATP) channels. This role was reversed by both 5-hydroxydecanoate, selectively closing mito K(ATP) channels, and PD-98509, MEK inhibitors. The present studies demonstrate that diazoxide prevents the onset and development of macrovascular disease in OLETF rats by inhibiting apoptosis directly via phosphorylated ERK increase in aorta ECs. Our findings establish the basis for the therapeutic potential of diazoxide in atherosclerotic disease.


Asunto(s)
Antihipertensivos/farmacología , Aorta Torácica/efectos de los fármacos , Apoptosis/efectos de los fármacos , Diazóxido/farmacología , Endotelio Vascular/efectos de los fármacos , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Estado Prediabético/enzimología , Animales , Aorta Torácica/enzimología , Aorta Torácica/metabolismo , Aorta Torácica/patología , Apoptosis/fisiología , Ácidos Decanoicos/farmacología , Endotelio Vascular/citología , Endotelio Vascular/enzimología , Endotelio Vascular/metabolismo , Activación Enzimática/efectos de los fármacos , Quinasas MAP Reguladas por Señal Extracelular/antagonistas & inhibidores , Prueba de Tolerancia a la Glucosa , Hidroxiácidos/farmacología , Etiquetado Corte-Fin in Situ , Masculino , Fosforilación/efectos de los fármacos , Canales de Potasio/metabolismo , Estado Prediabético/tratamiento farmacológico , Estado Prediabético/metabolismo , Estado Prediabético/patología , Distribución Aleatoria , Ratas , Ratas Endogámicas OLETF
4.
J Am Col Certif Wound Spec ; 3(2): 33-41, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24527167

RESUMEN

Chronic venous disorders are common in the Western world. The current treatment of venous leg ulcers is unsatisfactory despite the availability of well-documented standards of care. Patients today are interested in alternative approaches to modern medicine. We have developed a wound-healing powder containing natural ingredients with absorptive, aromatic, antiseptic, and anti-inflammatory synergistic properties. This report describes 3 cases that were successfully treated with the powder, demonstrating the potential of herbal remedies in the clinical treatment of venous leg ulcers.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA